603707.SS SHH
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
1W: +3.1%
1M: +3.1%
3M: +9.8%
YTD: -18.4%
1Y: -28.4%
3Y: -37.5%
5Y: -66.3%
¥8.19 ($1.22)
+0.30 (+3.80%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$9.5B
-0.2% ▼
5Y CAGR: +13.4%
Total Liabilities
$3.0B
-18.9% ▼
5Y CAGR: +7.8%
Shareholders Equity
$6.5B
+11.9% ▲
5Y CAGR: +17.0%
Cash & Investments
$2.1B
+9.9% ▲
5Y CAGR: +37.7%
Total Debt
$2.1B
-1.1% ▼
5Y CAGR: +8.6%
Net Debt
$1.0B
+18.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $494M | $659M | $1.4B | $1.2B | $1.0B |
| Short-Term Investments | $846M | $260M | $1M | $682M | $1.1B |
| Cash & ST Investments | $1.3B | $918M | $1.4B | $1.9B | $2.1B |
| Net Receivables | $895M | $1.1B | $1.2B | $1.0B | $1.2B |
| Inventory | $4.5B | $4.9B | $5.6B | $4.2B | $3.7B |
| Other Current Assets | $173M | $211M | $306M | $168M | $29M |
| Total Current Assets | $6.8B | $6.9B | $8.3B | $7.3B | $7.0B |
| Property, Plant & Equip. | $533M | $827M | $1.2B | $1.2B | $1.2B |
| Goodwill & Intangibles | $277M | $315M | $338M | $595M | $926M |
| Long-Term Investments | -$843M | -$233M | $60M | $72M | -$972M |
| Other Non-Current Assets | $964M | $344M | $19M | $1M | $1.1B |
| Total Non-Current Assets | $952M | $1.3B | $1.7B | $2.3B | $2.5B |
| Total Assets | $7.7B | $8.2B | $10.0B | $9.5B | $9.5B |
| — Liabilities — | |||||
| Accounts Payable | $363M | $459M | $505M | $538M | $496M |
| Short-Term Debt | $2.1B | $1.6B | $2.0B | $1.6B | $1.2B |
| Deferred Revenue | $143M | $221M | $38M | $0 | $0 |
| Other Current Liabilities | $95M | $16M | $204M | $982M | $329M |
| Total Current Liabilities | $2.8B | $2.3B | $2.7B | $3.1B | $2.1B |
| Long-Term Debt | $1.1B | $475M | $997M | $506M | $818M |
| Other Non-Current Liab. | $6M | $6M | $0 | $83M | $6M |
| Total Non-Current Liabilities | $1.2B | $548M | $1.1B | $640M | $957M |
| Total Liabilities | $4.0B | $2.8B | $3.8B | $3.7B | $3.0B |
| — Equity — | |||||
| Common Stock | $934M | $1.2B | $1.6B | $1.6B | $1.6B |
| Retained Earnings | $2.2B | $2.8B | $3.4B | $3.1B | $3.7B |
| Accumulated OCI | $417M | $407M | $546M | $73M | $85M |
| Total Stockholders Equity | $3.7B | $5.4B | $6.2B | $5.8B | $6.5B |
| Total Liabilities & Equity | $7.7B | $8.2B | $10.0B | $9.5B | $9.5B |
| — Key Metrics — | |||||
| Total Debt | $3.3B | $2.0B | $3.0B | $2.1B | $2.1B |
| Net Debt | $2.8B | $1.4B | $1.6B | $876M | $1.0B |
| Total Investments | $3M | $26M | $62M | $754M | $83M |